Try Alerts Free   |   Login
Health Care › Services-Medical Laboratories

BDSX Price Correlated With Financials For Biodesix

Free historical financial statements for Biodesix Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 8 quarters since 2020. Compare with BDSX stock chart to see long term trends.

BDSX Stock Compared to Quarterly

BDSX Income Statement

Revenue, Net:11107000
Revenue Per Share:0.2639
Selling, General & Admin Expense:15114000
Research & Development Expense:2970000
Total Operating Expenses:21717000
Operating Income:-10610000
Income Taxes:0
Net Income:-13699000
Earnings Per Share, Basic:-0.34
Shares Outstanding, Basic Avg:42093514

BDSX Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:893000
Change in Accounts Receiveable:-992000
Net Cash from Operations:-10331000
Net Cash from Operations Per Share:-0.2454
Net Cash from Financing Activities:-2265000
Property, Plant & Equipment Purchases:777000
Net Cash from Investing Activities:-815000
Net Change in Cash & Equivalents:-13411000

BDSX Balance Sheet

Cash and Cash Equivalents:15261000
Accounts Receivable, Net:4449000
Total Current Assets:24118000
Property, Plant & Equipment, Net:4259000
Total Assets:63198000
Accounts Payable:2100000
Total Short-Term Liabilities:37415000
Total Liabilities:66101000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Strobeck Matthew   Director
869,565 sh at $1
$1,000,000
Buy
MASSARANY HANY   Director
130,434 sh at $1
$149,999
Buy
Watts Charles M   Director
43,478 sh at $1
$50,000
Buy
Kayyem Jon Faiz   Director
173,913 sh at $1
$200,000
Buy
SCHULER JACK W   Director and 10% Owner
8,695,652 sh at $1
$10,000,000
Buy
PATIENCE JOHN   Chairman
1,739,130 sh at $1
$1,999,999
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Birchview Capital, Lp
1,811,412 sh
 
$2,300
Wells Fargo & Company/Mn
768,826 sh
219,231 sh
40%
$984
$66
Essex Investment Management Co LLC
378,023 sh
378,023 sh
NEW
$480
$480
Vanguard Group Inc
239,656 sh
59,660 sh
33%
$305
$10
Cannell Peter B & Co Inc
205,605 sh
 
$261
Endurant Capital Management Lp
130,136 sh
-617 sh
0%
$165
-$49
Geode Capital Management, LLC
124,070 sh
27,282 sh
28%
$157
-$1
Millennium Management LLC
118,048 sh
728 sh
1%
$150
-$42
Bridgeway Capital Management Inc
100,000 sh
50,000 sh
100%
$127
$45
Morgan Stanley
56,961 sh
-16,928 sh
-23%
$71
-$51
Renaissance Technologies LLC
56,900 sh
56,900 sh
NEW
$72
$72
Allworth Financial Lp
55,853 sh
 
$71
Citadel Advisors LLC
Put options for 43,500 sh
43,500 sh
NEW
$55
$55
Blackrock Inc.
39,296 sh
2,055 sh
6%
$50
-$11
Citadel Advisors LLC
Call options for 34,900 sh
34,900 sh
NEW
$44
$44
Citadel Advisors LLC
31,611 sh
-12,689 sh
-29%
$40
-$33
Susquehanna International Group, Llp
Call options for 26,600 sh
-14,400 sh
-35%
$34
-$33
Northern Trust Corp
15,742 sh
-87,359 sh
-85%
$20
-$154
CPWM, LLC
15,497 sh
15,497 sh
NEW
$20
$20
Qube Research & Technologies Ltd
13,615 sh
-2,056 sh
-13%
$17
-$9
COMPANY PROFILE
Note 1 – Organization and Description of Business Biodesix, Inc. (the “Company”, “Biodesix”, “we” “us” and “our”), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company’s headquarters are in Colorado, with laboratories in Colorado and Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The Company performs its blood-based diagnostic tests in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. In May 2020, the Federal Drug Administration (FDA) granted Emergency Use Authorization (EUA) of the Bio-Rad SARS-CoV-2 Droplet Digital™ polymerase chain reaction (ddPCR) test to detect Coronavirus Disease 2019 (COVID-19) infection. In April 2020, the FDA authorized the Platelia SARS-CoV-2 Total Ab test to detect COVID-19 antibodies. Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety. Blood-Based Lung Tests The Company offers five blood-based lung cancer tests across the lung cancer continuum of care: Diagnosis • Nodify XL2® and Nodify CDT® tests, marketed as our Nodify Lung ® Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.

Treatment & Monitoring • GeneStrat ddPCR® and VeriStrat® tests, marketed as part of our new IQLung™ testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to establish the patient’s prognosis and help guide treatment decisions. The GeneStrat ddPCR tumor profiling test and the VeriStrat immune profiling test have a 36-hour average turnaround time, providing physicians with timely results to facilitate treatment decisions.

• GeneStrat NGS™ (NGS) test, also marketed as part of our new IQLung testing strategy, our 72-hour blood-based NGS test, was launched in November 2021 to a select group of physicians, with national launch in January 2022. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner.

COVID-19 Tests We operate and have commercialized the Biodesix WorkSafe testing program, under which the Company offers three SARS-CoV-2 tests: • Bio-Rad SARS-CoV-2 ddPCR test, which is FDA EUA authorized to be performed by Clinical Laboratory Institute Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of infection by the SARS-CoV-2 virus.

• Platelia SARS-CoV-2 Total Ab test, which is an antibody test, FDA EUA authorized, intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection.

• cPass™ SARS-CoV-2 Neutralization Antibody test , which is the first blood-b

Data imported from Biodesix Inc. SEC filings. Check original filings before making any investment decision.